Valo CEO David Berry (Flagship Pioneering)

Look­ing to blend AI and hu­man da­ta, Va­lo Health scores new fi­nanc­ing to test drug dis­cov­ery plat­form in on­col­o­gy, be­yond

Com­pa­nies look­ing to bring ma­chine learn­ing in­to drug dis­cov­ery are a dime a dozen, but Boston-based Va­lo Health be­lieves its pro­pri­etary plat­form could give it a leg up in iden­ti­fy­ing can­di­dates for a range of ther­a­peu­tic ar­eas. Now, in­vestors are plac­ing a big down pay­ment to see if Va­lo is right.

Va­lo Health, which aims to merge AI with hu­man da­ta to for­mu­late can­cer ther­a­peu­tics and be­yond, has closed a $190 mil­lion Se­ries B fi­nanc­ing round. Va­lo said the fi­nanc­ing will ex­pe­dite sev­er­al new ther­a­peu­tic pro­grams us­ing the com­pa­ny’s nov­el drug de­vel­op­ment plat­form.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.